EUCTR2006-000435-99-CZ进行中（未招募）不适用
A Randomized, Double Blind, Placebo Controlled Multicenter Study to Assess the Efficacy and Safety of nasal spray ANTIRIN® and NASIC® in the Treatment of Allergic Rhinitis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Zentiva a.s.
- 入组人数
- 207
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •allergic rhinitis in last 2 years at least
- •positive skin test or specific IgE to allergens in the medical history
- •patients between 18 – 60 years, males and females
- •informed consent form signed
- •he patient can be reached by phone
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Asthma, with the exception of mild intermittent asthma
- •Systemic corticoids taken in last 1 month
- •Immunotherapy started in less than 1 month prior to the enrollment
- •antihypertensive drugs that may influence nasal congestion within 7 days prior to inclusion ( beta blockers, ACE inhibitors, alpha adrenergic antagonists i.e. prazosin,)
- •MAO inhibitors and other drugs with hypertensive potential within 7 days prior to inclusion
- •Chronic use of concomitant medications (e.g., tricyclic antidepressants) that would affect assessment of the effectiveness of the study medication
- •Documented evidence of acute or significant chronic sinusitis, as determined by the
- •individual investigator
- •Patients with history of hypersensitivity to the study medication or its excipients
- •Rhinitis medicamentosa
- •pregnant or lactating women
- •patients with history of nose surgery, after the injury of the facial skelet, after actinotherapy of the facial region
- •patients with the history of endocrine disease
- •patients with the history of narrow angle glaucoma
- •patients with the history of nasal polyps
- •any other disease or condition which may interfere with study assessments as judged by the investigator
- •alcohol or drug abuse
- •patients taking part in any other clinical trial or having participated in a clinical trial within the previous 3 months
- •clinically significant renal/hepatic impairment or serious heartdisease and uncontrolled hypertension
- •patients with pheochromocytoma
- •patients presenting any malignant disease
- •patients likely not to comply with the study procedures or with difficulties to understand the study procedures as judged by the investigator
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double Blind, Placebo Controlled Multicenter Study to Assess the Tolerability and Safety of ANTIRIN® nasal spray and drops in two Age Groups of Children with Acute RhinitisRinitis acutaMedDRA version: 8.1Level: LLTClassification code 10039083Term: RhinitisEUCTR2006-005461-19-CZZentiva a.s.240
Unknown
3 期
A clinical trial of Intravenous Aviptadil along with standard treatment in Subjects Hospitalized with Respiratory failure/acute respiratory distress syndrome associatedwith severe Coronavirus Disease (COVID-19).CTRI/2021/06/034373MSN Laboratories Private Limited74
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients - NDCMV disease in high risk kidney transplant recipientsMedDRA version: 6.1Level: PTClassification code 10011831EUCTR2005-002817-19-ITROCHE316
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. - The RUBY-1 studyThe investigation will be carried out on subjects with Acute Coronary Syndromes.MedDRA version: 12.0Level: LLTClassification code 10049166Term: Coronary artery thrombosis prophylaxisEUCTR2008-005972-29-GBAstellas Pharma Europe B.V.1,264
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. - The RUBY-1 studyEUCTR2008-005972-29-HUAstellas Pharma Europe B.V.1,264